HORSHAM, Pa.--(BUSINESS WIRE)--Aug. 3, 2006--Neose Technologies, Inc. (Nasdaq-GM:NTEC) today announced that it received a research milestone payment from Novo Nordisk A/S (NYSE:NVO) under a license agreement entered into in November 2003 for the use of Neose’s GlycoPEGylation(TM) technology to develop next-generation versions of Factors VIII and IX. The Company is also working with Novo Nordisk to develop a next-generation version of Factor VIIa.
